- Home
- EXEL vs RDY Comparison
EXEL vs RDY Comparison
Compare EXEL & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- RDY
- Stock Information
- Founded
- EXEL 1994
- RDY 1984
- Country
- EXEL United States
- RDY India
- Employees
- EXEL N/A
- RDY N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- EXEL Health Care
- RDY Health Care
- Exchange
- EXEL Nasdaq
- RDY Nasdaq
- Market Cap
- EXEL 10.0B
- RDY 11.9B
- IPO Year
- EXEL 2000
- RDY N/A
- Fundamental
- Price
- EXEL $34.59
- RDY $14.81
- Analyst Decision
- EXEL Buy
- RDY Buy
- Analyst Count
- EXEL 17
- RDY 1
- Target Price
- EXEL $32.18
- RDY $17.00
- AVG Volume (30 Days)
- EXEL 1.7M
- RDY 1.4M
- Earning Date
- EXEL 02-04-2025
- RDY 01-28-2025
- Dividend Yield
- EXEL N/A
- RDY 3.97%
- EPS Growth
- EXEL 441.02
- RDY 4.63
- EPS
- EXEL 1.55
- RDY 0.76
- Revenue
- EXEL $2,081,598,000.00
- RDY $3,579,112,656.00
- Revenue This Year
- EXEL $20.59
- RDY $13.39
- Revenue Next Year
- EXEL $1.50
- RDY $8.35
- P/E Ratio
- EXEL $22.41
- RDY $19.23
- Revenue Growth
- EXEL 17.31
- RDY 12.37
- 52 Week Low
- EXEL $19.20
- RDY $13.26
- 52 Week High
- EXEL $36.97
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- EXEL 51.61
- RDY 56.04
- Support Level
- EXEL $34.30
- RDY $14.45
- Resistance Level
- EXEL $36.22
- RDY $14.85
- Average True Range (ATR)
- EXEL 0.75
- RDY 0.16
- MACD
- EXEL -0.29
- RDY 0.08
- Stochastic Oscillator
- EXEL 25.09
- RDY 90.91
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.